ado-5030
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2026 (NCT07281274)
Timeline
2020s
- Jan 1, 2026
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- Adenosine receptorANTAGONIST
Adenosine receptor antagonist
- Adenosine receptor A1 (ADORA1) ↗
- Adenosine receptor A2b (ADORA2B) ↗
- Adenosine receptor A3 (ADORA3) ↗
- Adenosine receptor A2a (ADORA2A) ↗
- Adenosine A1 receptor
- Adenosine A2a receptor
- Adenosine A2b receptor
- Adenosine A3 receptor
- Adenosine A2 receptor
- Adenosine receptors; A1 & A3
- Adenosine receptors; A2a & A3
- Adenosine receptors; A2b & A3
- Adenosine receptors; A1 & A2
- Adenosine receptors; A1 & A2b
- Adenosine receptors; A1 & A2a
- Adenosine receptors; A2a & A2b
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07281274 | Phase 1 | Jan 1, 2026 | Adovate, University of Virginia |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adovate | Academic/Hospital | 1 | 1 | 1 | 2026 |
| University of Virginia | Academic/Hospital | 1 | 0 | 1 | 2026 |
2 organizations
Page 1 / 1